[HTML][HTML] mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD
Q Li, Y Lian, Y Deng, J Chen, T Wu, X Lai… - … Therapy-Nucleic Acids, 2021 - cell.com
Mesenchymal stromal cells (MSCs) have shown significant heterogeneity in terms of
therapeutic efficacy for inflammatory bowel disease (IBD) treatment, which may be due to an …
therapeutic efficacy for inflammatory bowel disease (IBD) treatment, which may be due to an …
Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue
X Liu, D Zuo, H Fan, Q Tang, Z Shou, D Cao… - Journal of molecular …, 2014 - Springer
Bone marrow-derived mesenchymal stem cells (BMSCs) are attractive candidates for tissue
regeneration and immunoregulation in inflammatory bowel disease. However, their in vivo …
regeneration and immunoregulation in inflammatory bowel disease. However, their in vivo …
[HTML][HTML] Mesenchymal stem cells and CXC chemokine receptor 4 overexpression improved the therapeutic effect on colitis via mucosa repair
Z Chen, Q Chen, H Du, L Xu… - Experimental and …, 2018 - spandidos-publications.com
The present study intended to observe the homing capability and therapeutic effect of CXC
chemokine receptor 4 (CXCR‑4) gene overexpressed bone marrow mesenchymal stem …
chemokine receptor 4 (CXCR‑4) gene overexpressed bone marrow mesenchymal stem …
Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice
XB Zheng, XW He, LJ Zhang, HB Qin… - Gastroenterology …, 2019 - academic.oup.com
Abstract Background and Objective Increasing interest has developed in the therapeutic
potential of bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of …
potential of bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of …
[HTML][HTML] Dual-functionalized MSCs that express CX3CR1 and IL-25 exhibit enhanced therapeutic effects on inflammatory bowel disease
Y Fu, J Ni, J Chen, G Ma, M Zhao, S Zhu, T Shi, J Zhu… - Molecular Therapy, 2020 - cell.com
Mesenchymal stem cells (MSCs) have shown great promise in inflammatory bowel disease
(IBD) treatment, owing to their immunosuppressive capabilities, but their therapeutic …
(IBD) treatment, owing to their immunosuppressive capabilities, but their therapeutic …
[HTML][HTML] Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10
R Hervás-Salcedo, M Fernández-García… - Stem Cell Research & …, 2021 - Springer
Abstract Background Mesenchymal stromal cells (MSCs) constitute one of the cell types
most frequently used in cell therapy. Although several studies have shown the efficacy of …
most frequently used in cell therapy. Although several studies have shown the efficacy of …
Characterization of intestinal mesenchymal stromal cells from patients with inflammatory bowel disease for autologous cell therapy
M Anbazhagan, D Geem… - Stem Cells …, 2023 - academic.oup.com
Therapy with mesenchymal stromal cells (MSCs) has shown promise in inflammatory bowel
disease—leveraging their immunosuppressive and regenerative properties. However, the …
disease—leveraging their immunosuppressive and regenerative properties. However, the …
Mesenchymal Stromal Cells: New Generation Treatment of Inflammatory Bowel Disease
S Wei, M Li, Q Wang, Y Zhao, F Du… - Journal of …, 2024 - Taylor & Francis
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal
tract, which has a high recurrence rate and is incurable due to a lack of effective treatment …
tract, which has a high recurrence rate and is incurable due to a lack of effective treatment …
[HTML][HTML] CCL2 and CXCL12 derived from mesenchymal stromal cells cooperatively polarize IL-10+ tissue macrophages to mitigate gut injury
Mesenchymal stromal cell (MSC)-based therapy for inflammatory diseases involves
paracrine and efferocytotic activation of immunosuppressive interleukin-10+(IL-10+) …
paracrine and efferocytotic activation of immunosuppressive interleukin-10+(IL-10+) …
[HTML][HTML] Protective effects of CXCR3/HO‑1 gene‑modified BMMSCs on damaged intestinal epithelial cells: Role of the p38‑MAPK signaling pathway
M Yin, Z Shen, L Yang… - … Journal of Molecular …, 2019 - spandidos-publications.com
The purpose of the present study was to investigate whether bone marrow mesenchymal
stem cells (BMMSCs) modified by CXC‑chemokine receptor type 3 (CXCR3) and heme …
stem cells (BMMSCs) modified by CXC‑chemokine receptor type 3 (CXCR3) and heme …